A Phase Iii, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Andecaliximab Combined With Mfolfox6 As First-Line Treatment In Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma (Gamma-1).